However, the degree of MCL-1 dependence has generally been correlated with more aggressive lymphoma subtypes [101] and, therefore, while there is a rationale to explore MCL-1 inhibitors in indolent lymphomas, the anticipated efficacy may be lower. Here, MCL1 is linked to lymphoma.